Congressional Report Slams FDA, Drugmaker Over Approval of Alzheimer Drug Aduhelm
Physician’s Briefing Staff
THURSDAY, Dec. 29, 2022 (HealthDay News) -- The U.S. Food and Drug Administration approval process for the controversial…
Browsing Tag
ADUHELM
Congressional Report Slams FDA, Drugmaker Over Approval of Alzheimer’s Drug…
Robin Foster
THURSDAY, Dec. 29, 2022 (HealthDay News) -- The U.S. Food and Drug Administration's approval process for the controversial Alzheimer's drug…
Alzheimer’s Patient Advocates File FOIA Seeking Answers on Discriminatory Medicare…
Washington, D.C., April 15, 2022 (GLOBE NEWSWIRE) -- Today, UsAgainstAlzheimer’s announced their latest effort to demand answers from the Centers for Medicare and Medicare Services (CMS)…
The FDA approved a new drug to treat Alzheimer’s, but Medicare won’t…
Medicare finalized its decision to restrict its coverage of Aduhelm, Biogen’s new Alzheimer’s disease drug, on April 8, 2022.
The decision means only patients who have enrolled in…
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials
For the past few months, Medicare officials have been inundated with impassioned pleas about how to handle coverage of the controversial new Alzheimer’s drug Aduhelm.Advocacy groups for…
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data…
CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed…
Biogen profit forecast misses estimates as Aduhelm weighs By Reuters
© Reuters. FILE PHOTO: A test tube is seen in front of displayed Biogen logo in this illustration taken, December 1, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) -Biogen…
Medicare Proposes to Cover Aduhelm Only for Patients in Clinical Trials
After Biogen’s price cut, advocacy groups for Alzheimer’s patients urged C.M.S. to lower the premium increase. On Monday, the secretary for health and human services, Xavier Becerra, said…
ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel …
TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and…
How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimer’s Drug
For more than a decade,
Biogen Inc.
BIIB -0.99%
worked on a new drug for Alzheimer’s disease that seemed to have blockbuster…